Hedging Your Bets Ahead of Amgen v Sanofi: Anticipating How the Supreme Court’s Enablement Ruling Will Affect Biologic Patent Portfolio Strategies

June 27, 2023 9:15am

Maureen A. Bresnahan
Assistant General Counsel
Eisai Inc.

Ivan M. Poullaos
Winston & Strawn LLP

Daniel Margolis
Allen & Overy LLP

John J. Molenda
Steptoe & Johnson LLP


Jason Murata
Axinn, Veltrop & Harkrider LLP

  • Devising alternate strategies for drafting enforceable claims
    • Outlining the scope of appropriate claims for antibodies
  • Implementing new strategies for drafting enforceable claims in view of the Supreme Court’s decision
  • Understanding the nuances between written description and enablement
    • Why did the Supreme Court decline to hear Kite v Juno?
  • Reconciling whether written description is met when the specification discloses formulas